Skip to content
BOLUS

Signal from the log

RegCell

44 M$ · Series A · United States · Biotech

RegCell convertit les lymphocytes T responsables d'une maladie auto-immune en lymphocytes T régulateurs, les cellules qui empêchent le système immunitaire de s'attaquer à l'organisme. Sa plateforme dite de reprogrammation épigénétique ne recourt à aucune ingénierie génétique. La biologie vient de Shimon Sakaguchi, cofondateur, prix Nobel de médecine 2025. Aucun essai clinique n'est ouvert, le tour finance le dépôt du dossier.

Article

Announced on , logged by the watch of 15 September 2026.

Operation
Funding round
Announced amount
44 M$
Stage
Series A
Country
United States
Sector
Biotech

What the log says

Editorial note, in French

Sujet traité. L'article donne les sources et la position de Bolus.

The investors

Led by Playground Global , with Global Brain , Mitsui Chemicals , LG Technology Ventures , Alumni Ventures , Medical Incubator Japan

Read the article on this operation (in French)

Provenance
Source businesswire,endpoints
Logged on 15 September 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Article The operation led to an article, with its sources checked one by one.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.

One address, nothing else.

One letter a week, on Fridays: the week's funding rounds, the funds named, the amounts double checked. The list is never sold, one click to unsubscribe. The letter is written in French.

Email confirmation before any subscription. The list is never sold. What Bolus knows about you is written on the privacy page (in French).